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New insights into the molecular pathophysiology of polycystic probably operate in concert during renal tubular cyst
kidney disease. Polycystic kidney diseases are characterized formation and progressive enlargement.
by the progressive expansion of multiple cystic lesions, which Three different genes have now been cloned that arecompromise the function of normal parenchyma. Throughout
associated with mutations that cause polycystic kidneythe course of these diseases, renal tubular function and struc-
disease (PKD) [1–3]. PKD1 and PKD2 are linked toture are altered, changing the tubular microenvironment and
ultimately causing the formation and progressive expansion of the most common forms of autosomal dominant PKD
cyctic lesions. Renal tubules are predisposed to cystogenesis (ADPKD), and Tg737 is associated with the orpk mouse
when a germ line mutation is inherited in either the human model of autosomal recessive PKD (ARPKD). Molecu-PKD1 or PKD2 genes in autosomal dominant polycystic kid-
lar genetic evidence suggests that the protein productsney disease (ADPKD) or when a homozygous mutation in
of these genes directly interact and that they participateTg737 is inherited in the orpk mouse model of autosomal
recessive polycystic kidney disease (ARPKD). Recent informa- in a common PKD disease pathway. These proteins may
tion strongly suggests that the protein products of these disease form a macromolecular signaling structure, the polycys-
genes may form a macromolecular signaling structure, the poly-
tin complex, that regulates fundamental aspects of renalcystin complex, which regulates fundamental aspects of renal
epithelial development and cell biology. The goal of thisepithelial development and cell biology. Here, we re-examine
the cellular pathophysiology of renal cyst formation and en- review is to re-examine the cellular pathophysiology of
largement in the context of our current understanding of the PKD in the context of our current understanding of the
molecular genetics of ADPKD and ARPKD. molecular genetics of PKD.
ALTERATIONS IN EXTRACELLULAR MATRIXStudies from a variety of experimental models and
human diseases implicate three major factors in renal Abnormal extracellular matrix (ECM) ultrastructure
cyst formation and progressive enlargement. Normal re- and biology are established characteristics of PKD [4, 5].
nal tubular absorptive epithelia can become cystic if (a) Interstitial alterations in PKD may simply reflect passive
hyperplasia, localized to a distinct nephron segment, re- changes occurring secondarily to tubular expansion or, as
quires accommodation of an increased cell mass; (b) a recent report suggests, may reflect abnormal interstitial
secretion, as opposed to absorption, leads to the net fibroblast biology. Fibroblasts from ADPKD kidneys are
accumulation of intratubular fluid; or (c) extracellular hyperproliferative in vitro and hyperresponsive to acidic
matrix abnormalities alter the epithelial microenviron- fibroblast growth factor (a-Fgf) [6]. Fibroblast prolifera-
ment so that abnormal cell–matrix interactions result in tion and the consequent increase in ECM deposition
abnormal epithelial hyperplastic and secretory activity. in vivo may contribute to the abnormal cystic tubular
These processes are not mutually exclusive, may reflect microenvironment observed in ADPKD kidneys [4, 5].
some characteristics of undifferentiated epithelium, and Active remodeling, or degradation of the ECM, is
a regulated developmental process that is mediated by
several proteases, including matrix metalloproteinases
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(MMPs) and cysteine proteinases [5]. MMPs are, in turn,Tg737, extracellular matrix, cell proliferation.
regulated by secreted proteins known as tissue inhibitors
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effect alterations in the ECM composition and cell– [14, 17]. In addition to methodological differences, these
matrix interactions. disparate data may be somewhat reconciled by analysis
Cathepsins are lysosomal cysteine proteinases that are of the developmental profile of Na,K-ATPase activity.
capable of degrading ECM directly or through the pro- In developing murine kidneys, transient apical expres-
teolytic activation of metalloproteinases. Alterations in sion of Na,K-ATPase is a normal feature of collecting
the levels of lysosomal proteinases have been observed tubule development [18]. Furthermore, Na,K-ATPase
in ADPKD and the Cy rat model of PKD [8, 9]. Addi- persists longer in cystic collecting tubules of murine cys-
tional data suggest that intracellular processing or traf- tic (cpk) kidneys, suggesting that altered fluid dynamics
ficking of cathepsins to lysosomes is abnormal in epithe- may contribute to early cystogenesis. The persistence of
lia from this rodent model [8, 9]. a transient developmental phenotype in cystic epithelia
Primary cystic tubule cell cultures from ADPKD kid- implies altered differentiation and commitment of these
neys exhibit both a decreased amount and an increased cells to an abnormal developmental pathway.
complexity of proteoglycan modifications [10]. Wide- Chloride secretion through the cystic fibrosis trans-
spread alterations in the proteoglycan composition of membrane receptor (CFTR) has recently been impli-
cell surface and extracellular components undoubtedly cated in the pathway of fluid secretion in ADPKD cystic
change the ECM and tubular microenvironment. Consti-
epithelia [19]. CFTR is a cAMP-dependent chloride
tutive alterations in the microenvironment may promote
channel that is required for chloride secretion and fluidaltered cell–cell and cell–matrix biology and underlie
production in airway epithelium [20]. In vitro experi-proliferative and secretory abnormalities in cystic tubu-
ments suggest that forskolin-stimulated chloride secre-lar epithelia [11].
tion could provide the electrochemical drive that medi-
ates fluid secretion in cystic epithelia [14, 21, 22]. Using
FLUID SECRETION IN HUMAN AUTOSOMAL primary epithelial cultures from ADPKD cysts, Davidow
DOMINANT POLYCYSTIC KIDNEY DISEASE et al [23] and Hanaoka et al [24] demonstrated that
Polycystic kidney disease is characterized by the pro- CFTR is expressed on the apical cell surface of cystic
gressive expansion of multiple cystic lesions, which com- epithelia and that the electrochemical properties of for-
promise normal parenchyma. In ADPKD, a majority of skolin-induced chloride secretion are identical to those
these lesions lack afferent and efferent tubule connec- of CFTR-mediated transport. Although not conclusive,
tions, suggesting that cysts that arise from tubular seg- these findings suggest that ADPKD cystic epithelia may
ments become disconnected from the influx of glomeru- use an apical CFTR Cl2 channel to facilitate ion and
lar filtrate and tubular flow at some stage of their fluid secretion. Further investigation will clarify the roles
development [12]. The development and growth of a of CFTR, other newly identified Cl2 channels, additional
cyst thus requires a net influx of fluid (that is, tubular anion transporters, and basolateral cell surface trans-
secretion) to prevent collapse of the cyst walls. The trans- porters in tubular epithelial cell secretion in PKD.
formation of normal absorptive epithelium into cystic Tanner et al have suggested a link between secretion
secretory epithelium is a key factor in cyst pathophysi- and proliferation in PKD epithelium [25]. Stretching
ology. monolayers of Madin-Darby canine kidney (MDCK)
Analysis of intact isolated cysts and monolayer culture cells for eight or more hours caused a significant increase
of cystic ADPKD epithelia demonstrated that fluid se-
in BrdU-labeled cells, indicating that stretch induces pro-
cretion can be induced by native cyst fluid or activation
liferation [25]. In addition, MDCK collagen-gel cysts ex-of the adenylate cyclase signal transduction pathway by
hibited a 37% increase in cyst volume and a 30% increaseforskolin or cAMP [13–15]. In the absence of stimulation,
in BrdU-labeled cells after a 2.5-hour exposure to cAMP,these epithelia absorbed fluid in a manner similar to
which induces fluid secretion in this in vitro system. Al-wild-type tubules, suggesting that cystic epithelia is not
though cAMP itself may induce cells to proliferate [26],terminally committed to secretion. The presence of stim-
these data suggest a potential link between secretion andulatory agents in cystic fluid and the potential for normal
proliferation in PKD.fluid absorption in cystic epithelium present a potential
Analyses of microdissected cystic tubule segmentstarget for future development of antisecretory, cyst-
from several animal models demonstrate physical prop-reduction therapies [14].
erties consistent with deformation caused by stretch [27],Initial investigations implicated the mislocalization of
yet ECM from normal and cystic tubules respondedthe Na,K-ATPase as the possible mechanism of fluid
equally to increased hydrostatic pressure and mechanicalsecretion in PKD [16]. Additional studies have suggested
deformation. These data are consistent with the possibil-that normal structural and functional Na,K-ATPase is
ity that repetitive cycles of “secretion-stretch-prolifera-localized to basolateral cell surfaces in cystic epithelia
(abstract; Ross et al, J Am Soc Nephrol 5:634, 1994) tion” may contribute to cyst enlargement in PKD.
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PROLIFERATION brosis, and interstitial inflammatory infiltrates [34]. Hy-
perplasia in this mouse model appears to be, in part, aTubular hyperplasia is a primary morphological find-
compensatory response to increased apoptosis duringing in all described human renal cystic diseases [28].
kidney development (discussed later in this article).Human and experimental data provide strong evidence
that abnormal proliferation in tubular epithelial cells Apoptosis in the kidney
plays a crucial role in cyst development and/or growth
Apoptosis, or programmed cell death, uses molecularin renal cystic disease [29].
pathways to ablate individual cells in response to exter-
nal stimuli or developmental genetic programs [37]. Dur-Hyperplasia in human cystic epithelia
ing kidney development, high levels of apoptosis areNadasdy et al determined the proliferative index, as
localized to the nephrogenic zone and the developingassessed by proliferating cell nuclear antigen, in cystic
medullary papilla [38]. Apoptosis appears to be the de-and noncystic tubule segments from ADPKD, ARPKD,
fault pathway for removing uninduced mesenchymeand acquired renal cystic disease kidneys [30]. Cystic
from the developing nephron. Curiously, the nephro-epithelia from these different forms of PKD exhibited
genic zone is a rapidly dividing population of cells thatsimilar elevated levels of proliferation. Analysis of non-
also exhibits a high frequency of apoptosis, a paradoxicalcystic regions within diseased kidneys revealed an ele-
motif reiterated in PKD.vated proliferative index in tubule segments from which
cysts in these different forms of PKD are believed to Apoptosis and proliferation are dysregulated in
originate, such as the collecting duct in ARPKD, distal autosomal dominant polycystic kidney disease
tubule in ADPKD, and both proximal and distal tubules
Recent reports have demonstrated that kidneys fromin acquired renal cystic disease. These observations sug-
patients with PKD exhibit high levels of apoptosis andgest that increased proliferation precedes overt cyst for-
cellular proliferation [30, 39, 40]. Lanoix et al observedmation and is thus a primary event in the disease
that the c-myc and bcl-2 genes are dramatically up-regu-pathway.
lated in renal cysts from ADPKD [39]. High levels of
c-myc and bcl-2 suggest inappropriate regulation of theProto-oncogene overexpression in human polycystic
proliferative/apoptosis pathways in ADPKD.kidney disease
A number of molecular changes have been shown to Apoptosis in murine models of
occur in polycystic kidneys from humans and several polycystic kidney disease
mouse models of PKD, including the increased expres- Using transgenic and targeted mutagenesis technolo-
sion of the c-myc, c-fos, c-jun, c-ha-ras and c-ki-ras proto- gies, the molecular pathways of apoptosis and prolifera-
oncogenes [31–33]. It is not yet clear whether these tion have been dysregulated, resulting in abnormal meta-
changes play an early role in progression of the disease nephric development and progressive cystic degener-
in human PKD or secondarily reflect changes in the ation. The SBM transgenic mouse overexpresses the
microenvironment of cystic lesions. Evidence from mu- c-myc cDNA under the control of the b-globin promoter
rine models suggests that early expression of proto-onco- and SV40 enhancer [34]. Adult transgenics die by four
genes may be sufficient to induce hyperplasia and predis- months of age from kidney disease, which is character-
pose tubules to cystic disease [34]. ized by tubular cysts, glomerulosclerosis, interstitial fi-
brosis, and interstitial inflammatory infiltrates. The tem-
Proto-oncogene–induced proliferation in murine poral and spatial pattern of elevated c-myc expression
polycystic kidney disease in these transgenics correlates with that of increased
Transgenic overexpression experiments demonstrated proliferation, apoptosis, and cystogenesis in glomeruli
that ras-induced tumor formation is preceded by hyper- and tubules.
plasia [35]. Recently, Gilbert et al used the promoter AP-2b is a transcription factor that negatively regu-
from the L-type pyruvate-kinase gene to drive expres- lates apoptosis by repressing the transcriptional activa-
sion of the H-ras cDNA in several tissues, including liver tion of c-myc target genes and is required for tubular
and kidney proximal tubules [36]. Expression of this cell survival during embryonic kidney development [41,
transgene induced hepatocarcinomas, cystic kidneys, and 42]. Targeted disruption of the AP-2b gene causes neona-
epididymal hyperplasia. Although renal failure was not tal lethality associated with small, cystic dysplastic kid-
the cause of mortality in these transgenics, H-ras expres- neys. Kidney lesions were paralleled by an elevation
sion in renal tubules appears to have predisposed these of apoptosis in distal tubules and collecting ducts. This
animals to renal cysts. phenotype suggests that AP-2b is required to suppress
Transgenic overexpression of c-myc in the SBM mouse apoptosis in renal tubules after they have formed.
Bcl-2 is a negative regulator of apoptosis [43, 44]. Tar-induces tubular cysts, glomerulosclerosis, interstitial fi-
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geted disruption of the bcl-2 gene causes elevated levels The renal cystic disease pathway involves the
of apoptosis during lymphoid and metanephric develop- epidermal growth factor receptor
ment and produces renal cystic hypoplasia/dysplasia [45– Transforming growth factor-a and EGF are secreted
48]. Sorenson et al also observed increased proliferation growth factor polypeptides, which are ligands for the
in affected and unaffected nephrons and apoptosis was EGFR. The EGFR is composed of an extracellular li-
elevated in cystic epithelia [49]. Bcl-2–deficient mice pro- gand binding domain, a transmembrane region, and a
vide additional support that the dysregulation of apopto- cytoplasmic tyrosine kinase domain. Signal transduction
sis and cellular proliferation play a role in the develop- through the EGFR axis involves ligand binding, dimer-
ment and enlargement of renal cystic lesions. ization, tyrosine kinase activation, autophosphorylation
of EGFR dimers, and phosphorylation of the immediateA role for growth factor overexpression in polycystic
downstream targets of the EGFR [60]. These targetskidney disease
propagate a signal transduction pathway, which stimu-
Overexpression of hepatocyte growth factor (HGF), lates proliferation or differentiation, depending on the
keratinocyte growth factor (KGF), and transforming cell type.
growth factor-a (TGF-a) in transgenic mice have gener- Epidermal growth factor and TGF-a are produced
ated several additional mouse models that provide in- from processing of large polypeptides. In the kidney,
sight into the pathophysiology of renal cyst formation EGF is produced in the thick ascending limb of Henle
and progressive enlargement. HGF is a secreted growth and distal convoluted tubules (abstract; Salido et al, Clin
factor that is the primary ligand for the c-met tyrosine Res 39:112A, 1991) [61]. EGFR is normally expressed
kinase receptor. During metanephric development, c-met on the basolateral surface of renal tubules. This pattern
is expressed by epithelial cells, and HGF is expressed of EGF, TGF-a, and EGFR expression in normal kidney
by the surrounding mesenchyme, suggesting that they tubules suggests that constitutive low levels of EGFR
create a paracrine system during mesenchymal–epith- stimulation may play a role in maintaining normal renal
elial interactions [50, 51]. Recent experiments using
epithelium. Gattone et al studied the effect of exogenous
metanephric organ culture demonstrated that HGF plays
administration of EGF on cystic epithelium in cpk micea dynamic role in metanephric development [52]. Trans-
[62]. Although there was no significant alteration of cys-genic overexpression of HGF in tubular epithelium, un-
tic morphology, the administration of EGF from postna-der the inducible control of the metallothionein pro-
tal day 3 through 9 improved renal function. This sug-moter, causes glomerulosclerosis and tubular dilations
gests that growth factor and/or decreased apoptosis mayassociated with increased proliferation of glomerular and
improve renal function in this model. Although the func-tubule cells [53]. Although morbidity in these animals is
tion of renal TGF-a and EGF in normal kidney tubuleattributed to glomerulosclerosis, tubular hyperplasia and
development or repair is not fully understood, these li-resultant dilations resemble early tubular lesions in PKD.
gands have been shown to exert potent mitogenic effectsKeratinocyte growth factor is a member of the fibro-
on tubular epithelium [63, 64].blast growth factor family and is a ligand for KGFR, a
Substantial evidence demonstrates that the EGFR axissplice variant of FGFR2 [54, 55]. Expression of the hu-
is involved in the pathophysiology of PKD. Renal cystman KGF cDNA under the control of the human apoli-
formation has been correlated with the expression ofpoprotein E regulatory elements resulted in perinatal
specific transgenes or altered levels of endogenous geneslethality associated with epithelial hyperplasia in multi-
associated with cell proliferation. As described earlier,ple tissues, including liver, lung, pancreas, and kidney
transgenic models in which genes linked to proliferation[56]. Transgenic animals exhibited hyperproliferative
have been overexpressed (such as TGF-a and HGF)cystic lesions in medullary and cortical collecting ducts
develop PKD. Overproduction of EGF/TGF-a and over-associated with expression of KGFR.
expression of their receptor are two possible alterationsTransforming growth factor-a is a member of the epi-
that could up-regulate the EGFR axis. In fact, thedermal growth factor (EGF) family, which is expressed
involvement of the EGFR axis in PKD is more compli-during kidney development [57]. Overexpression of the
cated and involves alterations of ligand processing andTGF-a cDNA, under the control of the metallothionein
expression, and quantitative (increased levels) and quali-promoter, produced renal cystic lesions [58]. Crossing
tative (apical cell surface) expression of EGFR [65–68].this TGF-a transgene with pcy, a recessive murine PKD
Renal cyst fluid from ADPKD, ARPKD, and murinemutation, accelerated disease progression [59]. In addi-
and rat PKD models contains multiple EGF or EGF-tion to the TGF-a/pcy transgenic model of PKD, a grow-
like peptides in mitogenic concentrations (abstract;ing body of evidence suggests a potential role for the
Sweeney et al, J Am Soc Nephrol 7:1606, 1996) [69–71].TGF-a/EGF/EGF receptor (EGFR) axis in promoting
EGF is a potent mitogen for isolated cystic epithelia [72].epithelial hyperplasia and the growth of cysts after they
are initiated (discussed later in this article). TGF-a and EGF are cystogenic in murine embryonic
Murcia et al: New insights into PKD 1191
organ culture [73, 74] and normal human kidney cells life span is dramatically increased compared with orpk
homozygotes [77]. These data unequivocally establish agrown in three-dimensional collagen gels [75]. These
findings indicate that EGF and TGF-a can induce cysts direct role for the EGFR in the pathobiology of collect-
ing tubule cystogenesis.by stimulating cellular proliferation and that once a cyst
is formed, continued secretion of biologically active EGF
and TGF-a–like peptides can induce localized epithelia
SIGNALING
cell proliferation and cyst enlargement.
Proliferating epithelial cells of renal cysts appear mor-The expression of EGF receptor mRNA is signifi-
phologically less differentiated than noncystic tubularcantly elevated in primary cultures of cystic epithelia
epithelium. Morphological differences associated withderived from PKD patients [76]. EGFR protein is over-
this cystic phenotype include persistent expression ofexpressed and mislocalized to the apical and basolateral
clusterin, vimentin, and Pax-2, as well as polarity abnor-surfaces of cystic tubular epithelium in human ADPKD,
malities, including E-cadherin, cathepsins B and H, gela-human ARPKD, and murine models of ARPKD (cpk,
tinase A, TIMP, and apical EGFR expression [83–85].bpk, and orpk) (abstract; Avner and Sweeney, Pediatr
An immature epithelial phenotype and abnormal epithe-Res 37:359A, 1995) [67, 77, 78]. Because the apical cell
lial proliferation associated with renal cystic lesions hassurface is in direct contact with cystic fluid, apical local-
led to the evolution of the “maturation arrest” theoryization of the receptor places it in direct contact with a
of PKD [84].pool of EGF and TGF-a polypeptides. In addition, new
evidence indicates that the signal transduction pathways,
Altered polarity is not a global defect in polycystic
which are regulated by the EGFR axis, may qualitatively
kidney disease
differ when activated from the apical versus basolateral
The establishment of apical and basolateral membranecell surface (abstract; Amsler et al, J Am Soc Nephrol
domains is a dynamic multistage process requiring a hier-8:432A, 1997), suggesting that apical stimulation by
archy of steps. The initiation and maintenance of polar-EGF/TGF-a could illicit unique biological responses in
ization depend on cell–cell and cell–matrix adhesion.cystic epithelia.
In the absence of extracellular adhesion, epithelial cellsPrimary cultures of cystic epithelial cells from human
demonstrate few characteristics of polarized cells.ADPKD, human ARPKD, and several mouse models
Polarized organization of proteins in renal epitheliaof ARPKD maintain their abnormal apical localization
is the basis for the function of these cells. The spatialof EGFRs in vitro [68, 79]. Furthermore, these apical
arrangement and unique protein composition of apicalreceptors bind EGF with high affinity, autophosphory-
and basolateral domains facilitate cellular processes aslate, and transmit a mitogenic signal when stimulated [68,
diverse as vectorial transport of molecules across the cell79]. The activation of the apical EGFR axis stimulates
layer, differentiation, proliferation, cell migration, andtubular epithelial cells to proliferate [80].
morphogenesis.An analysis of the orpk animal model has provided
Although the phenotypic abnormalities of cysts anddirect evidence supporting a major role for the EGF/
cystic epithelia are numerous, specific proteins have beenTGF-a/EGFR axis in promoting cyst growth. Orpk is a
identified that are mislocalized, abnormally secreted, orrecessive insertional mutation that causes a dual hepato-
exhibit abnormal post-translational modifications [85].renal disease that models human ARPKD [81]. Cystic
The selective or limited polarized defects in PKD suggestcollecting tubules from orpk homozygotes possess ele-
that specific developmental pathways of epithelial polar-vated mRNA, protein and tyrosine kinase activity of the
ity and its maintenance are affected in the disease.EGFR, and EGFR protein is abnormally expressed in
The adhesion receptor proteins mediate cell–cell inter-both the apical and basolateral membranes [77, 79]. The
actions and are required for the establishment and main-in vivo role of EGFR overexpression in collecting tubule
tenance of epithelial polarity. Cadherin and integrin ad-cyst growth was definitively established by using the orpk
hesions act as nucleation sites for the localized assemblyand waved-2 (wa-2) mutations [77]. The wa-2 allele en-
of specialized cytoskeletal and signaling networks at thecodes a single amino acid change in EGFR that dram-
point of cell contacts. These signaling networks includeatically decreases EGFR tyrosine kinase activity and
guanosine triphosphate-binding proteins, components ofcauses wavy fur and curly vibrissae in homozygotes [82].
the ras pathway (SOS and Grb2), kinases, phosphatases,Wa-2;orpk double homozygotes were generated to ge-
and cytoskeletal proteins [86].netically test the role of reduced EGFR activity in the
Recent investigations have demonstrated that me-PKD disease pathway. Wa-2;orpk double homozygotes
chanical forces, generated through molecular interac-exhibit a dramatically reduced collecting tubule cystic
tions within the cytoskeletal architecture, play a centralindex, which correlated directly with reduced levels of
role in cell function. Cellular activities modulated bykidney EGFR tyrosine kinase activity. These double mu-
tants retain their ability to concentrate urine, and their cytoskeletal forces include growth, differentiation, apop-
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tosis, signal transduction, gene expression, and ECM re- Colon carcinoma cells, which have lost wild-type APC
protein, have elevated levels of b-catenin/transcriptionmodeling [87]. In PKD, all of these processes are altered,
suggesting that changes in the shape and orientation factor complexes that are constitutively active [95, 96].
Stabilizing the b-catenin/APC interaction blocks tubu-of the ECM-cytoskeletal-nuclear lattice may change the
orientation of interacting regulatory components, which logenesis in the MDCK epithelial cell model. Pollack et
al expressed N-terminal deleted b-catenin constructs,may ultimately lead to the altered cellular biology of
cystic epithelia. which form stable complexes with APC, in MDCK cells
and demonstrated that MDCK cysts, in three-dimen-The complex, dynamic process of polarization requires
the interpretation of numerous cues directing the site of sional collagen gels, failed to undergo cell migrations
and tubulogenesis in response to HGF treatment [97].assembly and the sequence of assembly of numerous
proteins necessary to facilitate this specialized organiza- Adhesion-mediated signaling, transcriptional regula-
tion, and epithelial tubulogenesis are regulated by com-tion. Alterations of the protein–protein interactions re-
quired in this process can lead to defects in proliferation, plex protein–protein interactions, which are exemplified
by the diverse functions of b-catenin. The phenotype ofdifferentiation, polarity, and morphogenesis, which may
lead to a pathological state such as PKD. Adhesion- cystic epithelial cells indicates that the primary genetic
lesions of PKD in humans and in animal models involvemediated signaling through b-catenin provides a para-
digm of how altered interactions can lead to a pathologi- proteins that regulate, perceive, or interpret the develop-
mental cues that establish and maintain mature renalcal state.
b-catenin is a multifunctional protein that engages in tubular epithelial characteristics. Molecular genetic anal-
ysis of the PKD1, PKD2, and Tg737 genes is providingat least three intracellular regulatory pathways: cell
adhesion, transcriptional regulation, and tubular mor- new insight into how mutations in these proteins may
alter epithelial cell biology, leading to the formation ofphogenesis [88]. Catenin/cadherin complexes provide a
structural link between cell–cell surface adhesions and cystic lesions.
the actin cytoskeleton. Tyrosine phosphorylation of
b-catenin disrupts the catenin/cadherin interaction re-
MOLECULAR GENETICS OF POLYCYSTIC
sulting in decreased cell adhesion [88]. b-catenin binds
KIDNEY DISEASE
EGFR and c-erbB-2, receptor tyrosine kinases, which
Evidence for a macromolecular polycystin complexupon ligand activation can lead to tyrosine phosphoryla-
tion of b-catenin [88, 89]. TGF-a and HGF transgenic Three different genes have now been cloned that are
associated with mutations that cause PKD [1]. PKD1overexpression, which provide mouse models for PKD,
may activate the b-catenin pathway through increased and PKD2 are linked to the most common forms of
ADPKD, and Tg737 is associated with the orpk mouseEGFR and c-met tyrosine phosphorylation of b-catenin.
b-catenin is also part of the Wnt signal transduction model of ARPKD. Polycystin 1 (PC1), the protein prod-
uct of PKD1, is a large transmembrane protein that maypathway [88, 90, 91]. In mammalian cells, b-catenin exists
in a large complex composed of glycogen synthase kinase regulate cell–cell and/or cell–matrix interactions at the
cell surface [98, 99]. Data from in vitro protein interac-3b (GSK-3b), adenomatous polyposis coli (APC), and
a newly discovered protein called conductin [92, 93]. In tions and heterologous expression systems suggest that
PC1 forms heterodimers with the PKD2 gene product,the absence of a Wnt ligand/receptor transmembrane
signal, b-catenin becomes phosphorylated by the GSK- polycystin 2 (PC2) [100, 101]. PC2 is an integral mem-
brane protein, which by structural motif analysis, may3b serine/threonine kinase, which targets b-catenin for
ubiquitin/proteasome degradation. APC and conductin be part of the Ca21 ion channel family [102]. Further in
vitro data suggest that PC2 forms homodimers in a do-binding in this complex may facilitate b-catenin phos-
phorylation by GSK-3b [92, 93]. The activation of the main separate from its heterodimeric interaction with
PC1 [100, 101]. Tg737 contains 10 copies of the tetratrico-Wnt receptor pathway blocks GSK-3b activity, allowing
b-catenin to accumulate as free cytoplasmic pools. Free peptide repeat (TPR) motif, suggesting that it may medi-
ate protein–protein interactions [81, 103]. Yeast two-b-catenin forms complexes with the T-cell factor/lym-
phoid enhancer factor-1 (TCF-LEF-1) family of tran- hybrid screens with Tg737 identified several potential
protein partners, including PC1, a-catenin, p120 catenin,scription factors [88, 90]. These complexes translocate
to the nucleus and regulate gene expression. Snx1, and HNF4 (abstract; Yoder et al, J Am Soc Nephrol
8:386A, 1997).Tubular morphogenesis is regulated by b-catenin/
APC interactions. The C terminus of APC encodes a Molecular genetic evidence suggests that the protein
products of these PKD disease genes participate in amicrotubule-binding site, and in actively migrating cells,
APC localizes near the ends of microtubule projections common PKD disease pathway and provides a “working
hypothesis” for critical analysis (Fig. 1). These data sug-[94]. Normally, b-catenin/APC interactions are transient
and associated with the active degradation of b-catenin. gest that PC1, PC2, and Tg737 form a macromolecular
Murcia et al: New insights into PKD 1193
Fig. 1. A speculative model of intracellular signaling pathways in polycystic kidney disease (PKD). This is a representation of the intracellular
signaling pathways that may be regulated by the polycystin complex. These pathways including cell adhesion, cell–matrix interactions, cytoskeletal
and microtubular dynamics, transcriptional and cell cycle regulation. The common phenotype of PKD, associated with mutations in PKD1, PKD2,
or Tg737, may result from disruption of the polycystin complex and subsequent deregulation of downstream pathways. The EGFR and cadherins
associate with b-catenin (b), a-catenin (a), and p120-catenin (p120), which provide attachments to the actin cytoskeleton. Tg737, like b-catenin,
may be linked to the actin cytoskeleton through interactions with a-catenin and p120-catenin. The polycystin complex is composed of Tg737,
polycystin 1 (PC1), and polycystin 2 (PC2) through their heterodimeric interactions in separate binding domains. Tg737 may link this complex to
the actin cytoskeleton through interactions with catenins. By binding to the as yet unidentified polycystin 1 ligand, there may be changes in the
intracellular Ca21 concentrations through PC2 calcium channel activity and release of Tg737. These responses, coupled with other as yet unidentified
protein–protein interactions, may initiate a signal transduction cascade, which ultimately leads to transcription regulation of genes, such as AP-1,
and regulation of epithelial cell biology. Release of Tg737 from the polycystin complex may induce cytoskeletal rearrangements and alter the
intracellular dynamics of Tg737 protein–protein interactions. Free Tg737 may influence the intracellular balance of b-catenin by competing for
a-catenin and p120-catenin and thus altering the distribution of b-catenin between free pools, complexes with APC, GSK3b (GSK) and conductin,
or complexes with TCF/LEF-1 (TCF). Also, the release of APC from the b-catenin complex may alter microtubule dynamics. Tg737 may also
potentiate gene regulation with HNF4 and regulate EGFR turnover through Tg737/Snx-1 (Snx) interactions. Alterations in the dynamics of these
protein–protein interactions may alter epithelial cell biochemistry, leading to abnormal differentiation, proliferation, and polarity.
regulatory/signaling structure at the cytoplasmic mem- The polycystin complex may respond to extracellular
brane, called the polycystin complex, that may regulate signals, mediated by the as yet unidentified polycystin
fundamental aspects of renal epithelial cell biology [1]. ligand, by initiating a signal transduction cascade involv-
Recent data suggest that forming the polycystin complex ing regulated Ca21 channel activity and dynamic protein–
may be required for function and stability of individual protein interactions. Release of Tg737 from the polycys-
components. PKD2 appears to be required for the stabil- tin complex may influence a-catenin/p120-catenin inter-
ity of PKD1; the loss of PKD2 causes rapid degradation
actions, including association of the polycystin complexof PKD1 (abstract; Ong et al, J Am Soc Nephrol 9:379A,
with the actin cytoskeleton and altered cell–cell adhe-1998) [101]. The common phenotype of PKD, associated
sion. Dynamic changes in the association of the polycys-with mutations in PKD1, PKD2, or Tg737, may result
tin complex with a-catenin/p120-catenin may influencefrom disruption of the polycystin complex and the subse-
quent deregulation of this emerging pathway. the levels of free b-catenin, b-catenin degradation, or
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b-catenin/cadherin interactions. The release of Tg737 ture tubular epithelium to cystic epithelium must involve
abnormal gene expression, which may directly cause ormay stabilize the EGFR/Snx1 interaction, stimulating
EGFR degradation. reinforce the alterations caused by disruption of the poly-
cystin complex. Further dissection of this emerging path-In renal epithelia, transcriptional regulation of several
target genes may be controlled by signals from the poly- way will hopefully illuminate the connections between
the primary genetic lesions and the changes in ECMcystin complex. Recent data support the existence of
a polycystin complex associated with proteins involved composition, fluid secretion, and proliferation, which
characterize the pathophysiology of renal cyst formation.in signal transduction and cell–cell adhesion. The
C-terminal cytoplasmic domain of PKD1 initiates activa-
tion of AP-1, a transcription factor that mediates a num-
FROM MOLECULAR INSIGHTS TO FUTURE
ber of cellular responses including proliferation, differ-
THERAPEUTIC APPLICATIONS
entiation, and apoptosis [104]. This signal transduction
The identification of critical components and interac-pathway may be initiated by G proteins. A G-protein
tions of PKD signal transduction pathways will provideactivation domain has been identified within the C-ter-
new opportunities to create therapeutic agents that tar-minal domain of PKD1, and in vitro, this domain binds
get processes responsible for cyst formation and growth.to and activates G proteins (abstract; Parnell et al, J Am
The ability to deliver a foreign gene along with theSoc Nephrol 9:380A, 1998). Consistent with initiating a
appropriate promoter elements into the mammalian kid-signal transduction cascade leading to AP-1 activation,
ney and to target this vector to appropriate cells is thein vitro expression of PKD1 and PKD2 activates protein
goal of renal gene therapy. Moullier et al demonstratedkinase C isozymes, c-Jun N-terminal kinase (JNK), and
that the introduction of a vector via the renal arteryp38 mitogen-activated protein kinase (abstract; Arnould
would selectively target cortical proximal tubular cells,et al, J Am Soc Nephrol 9:370A, 1998) [104]. Changes
whereas the introduction of the same vector via retro-in the intracellular distribution of b-catenin, through dy-
grade perfusion would specifically target tubular cellsnamic Tg737/catenin interactions or through the WNT
from the papilla and medulla [105]. This is particularlysignaling pathway (abstract; Kim et al, J Am Soc Nephrol
relevant in ARPKD, where cysts form and progressively9:377A, 1998) could affect the formation and nuclear
enlarge in collecting tubules.translocation of b-catenin/T-cell factor (TCF)/lymphoid
Selective targeting could be furthered enhanced byenhancer factor-1 (LEF-1) transcription factor com-
taking advantage of apical EGFR expression in ARPKDplexes. In addition, nuclear translocation of free Tg737
collecting tubule (CT). Apical EGFR in CT could bemay allow associations with transcription factors like
used to test EGFR-specific, potent tyrosine kinase inhibi-HNF4. Data from recent reports support physical inter-
tors or used to target other pharmacological agents toactions between the polycystin complex and structural
cystic cells [106, 107]. Using receptor-mediated endocy-components of apical focal adhesion points. Using anti-
tosis, synthetic peptides bound to an EGFR ligand couldbodies against the C terminus of PKD1, several proteins
be delivered to cells that express apical EGFRs via retro-were found to coprecipitate, including components of
grade perfusion. This strategy could introduce a thera-focal adhesion sites (viculin, paxillin, p130Cas, and
peutic vector in a compacted form to cystic CT. Wu etpp125FAK) and actin-binding proteins (actinin and
al reported that targeted delivery and persistent expres-talin) (abstracts; Geng et al, J Am Soc Nephrol 9:374A,
sion of a foreign gene is possible by using polycations1998; and Li et al, J Am Soc Nephrol 9:377, 1998).
such as poly-l-lysine, which can promote DNA compac-In human ADPKD and in the orpk animal model of
tion [108]. Using this approach, ligands such as trans-ARPKD, the polycystin complex would be disrupted by
ferrin, EGF, TGF-a, or synthetic peptides could be cova-mutations in or loss of PC1, PC2, or Tg737. Although
lently coupled to polycations to target foreign genes tothe polycystin complex and the interrelated pathways
PKD epithelia in vivo [108, 109].presented here offer only a speculative working model,
these emerging pathways provide the first insights into Reprint requests to Ellis D. Avner, M.D., Department of Pediatrics,
Rainbow Babies and Children’s Hospital, Mail stop 6003, Cleveland,a common PKD disease pathway. Disruption of the poly-
Ohio 44106-6003, USA.cystin complex may alter the ability of renal epithelial
E-mail: eda@po.cwru.edu
cells to execute their developmental programs correctly,
sense and respond to their microenvironment, or main-
tain their mature phenotype. The loss of polycystin com- APPENDIX
plex function may effect the regulation of several emerg- Abbreviations used in this article are: ADPKD, autosomal dominant
polycystic kidney disease; APC, adenomatous polyposis coli; ARPKD,ing downstream pathways, including the EGFR axis,
acquired renal polycystic kidney disease; CFTR, cystic fibrosis trans-b-catenin dynamics, the cytoskeleton, microtubules,
membrane receptor; ECM, extracellular matrix; EGF, epidermal
transcriptional regulation, cell cycle regulation (prolifer- growth factor; EGFR, epidermal growth factor receptor; GSK-3b, gly-
cogen synthase kinase 3b; HGF, hepatocyte growth factor; MDCK,ation/apoptosis), and cell adhesion. Divergence from ma-
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Madin-Darby canine kidney; PC1, polycystin 1; PC2, polycystin 2; JJ: The cystic fibrosis transmembrane conductance regulator me-
diates transepithelial fluid secretion by human autosomal domi-PKD, polycystic kidney disease; TGF-a, transforming growth factor-
a; wa-2, waved-2. nant polycystic kidney disease epithelium in vitro. Kidney Int
50:208–218, 1996
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